

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
2 September 2004 (02.09.2004)






PCT

(10) International Publication Number
WO 2004/073642 A3

- (51) International Patent Classification⁷: **C07D 239/22**, A61K 31/513, C07C 225/18, C07D 231/06, 239/26, 281/10, A61K 31/135, 31/415, 31/505, 31/554
- (21) International Application Number: PCT/US2004/004765
- (22) International Filing Date: 18 February 2004 (18.02.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/448,629 19 February 2003 (19.02.2003) US
- (71) Applicant (for all designated States except US): **ACA-DIA PHARMACEUTICALS INC.** [US/US]; 3911 Sorrento Valley Blvd., San Diego, California 92121 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **OLSSON, Roger** [SE/SE]; Andreegatan 8, S-211 49 Malmo (SE).
- (74) Agent: **HART, Daniel; KNOBBE, MARTENS, OLSON & BEAR, LLP**, 2040 Main Street, 14th Floor, Irvine, California 92614 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**
— of inventorship (Rule 4.17(iv)) for US only
- Published:**
— with international search report

[Continued on next page]

(54) Title: 2-AMINOETHYL SUBSTITUTED PYRIMIDIN-2-ONES, CYCLOPROPANES, PYRAZOLINES, PYRIMIDINES AND BENZOTHAIAZEPINES AND THEIR USE AS UROTENSIN II AND SOMATOSTATIN 5 RECEPTOR LIGANDS



(57) Abstract: The present invention provides a combinatorial approach to a library of novel compounds having four diversity points. The compounds provide for the mapping of urotensin II and somatostatin 5 receptors by differential binding of said receptors. Accordingly, the invention relates in a first aspect to novel compounds of the general formula I to V or salts thereof. The present invention further relates to a method of treating diseases for which modulation of the urotensin II receptor produces a physiologically beneficial response in said disease, such as those associated with CNS function and cardiovascular diseases. The present invention further relates to pharmaceutical compositions comprising these agents for the treatment of these diseases adapted to modulate the urotensin II receptor.



(88) Date of publication of the international search report:

17 March 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.